1. Home
  2. PHAR vs XRX Comparison

PHAR vs XRX Comparison

Compare PHAR & XRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • XRX
  • Stock Information
  • Founded
  • PHAR 1988
  • XRX 1906
  • Country
  • PHAR Netherlands
  • XRX United States
  • Employees
  • PHAR N/A
  • XRX N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • XRX Computer peripheral equipment
  • Sector
  • PHAR Health Care
  • XRX Technology
  • Exchange
  • PHAR Nasdaq
  • XRX Nasdaq
  • Market Cap
  • PHAR 731.1M
  • XRX 674.2M
  • IPO Year
  • PHAR N/A
  • XRX N/A
  • Fundamental
  • Price
  • PHAR $10.00
  • XRX $5.12
  • Analyst Decision
  • PHAR Strong Buy
  • XRX Sell
  • Analyst Count
  • PHAR 3
  • XRX 3
  • Target Price
  • PHAR $30.00
  • XRX $9.00
  • AVG Volume (30 Days)
  • PHAR 3.6K
  • XRX 3.4M
  • Earning Date
  • PHAR 07-31-2025
  • XRX 07-24-2025
  • Dividend Yield
  • PHAR N/A
  • XRX 9.73%
  • EPS Growth
  • PHAR N/A
  • XRX N/A
  • EPS
  • PHAR N/A
  • XRX N/A
  • Revenue
  • PHAR $320,708,000.00
  • XRX $6,176,000,000.00
  • Revenue This Year
  • PHAR $13.31
  • XRX $0.80
  • Revenue Next Year
  • PHAR $7.68
  • XRX $14.78
  • P/E Ratio
  • PHAR N/A
  • XRX N/A
  • Revenue Growth
  • PHAR 24.13
  • XRX N/A
  • 52 Week Low
  • PHAR $6.65
  • XRX $3.45
  • 52 Week High
  • PHAR $12.61
  • XRX $12.29
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 43.61
  • XRX 43.85
  • Support Level
  • PHAR $9.99
  • XRX $5.14
  • Resistance Level
  • PHAR $10.59
  • XRX $5.90
  • Average True Range (ATR)
  • PHAR 0.35
  • XRX 0.27
  • MACD
  • PHAR -0.14
  • XRX -0.05
  • Stochastic Oscillator
  • PHAR 7.45
  • XRX 11.29

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About XRX Xerox Holdings Corporation

Xerox Holdings Corp is an original equipment manufacturing and software company. Xerox operates in one segment--design, development, and sale of printing technology and related solutions--while deriving 60% of its revenue from the U.S. and 40% from international markets. The company is an OEM of multifunction printers, or MFPs (printers that can print, copy, and scan), focusing on large enterprise markets. Apart from equipment, the company provides post-sales services like managed print services help to bring smart servicing and efficiencies to how employers use their print/copy equipment. Xerox is attempting to enter new markets like digital print packaging solutions and printed electronics.

Share on Social Networks: